Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

PURPOSE: Evaluate the activity of everolimus (RAD001) in combination with octreotide long-acting repeatable (LAR) in patients with advanced low- to intermediate-grade neuroendocrine tumors. METHODS: Treatment consisted of RAD001 5 mg/d (30 patients) or 10 mg/d (30 patients) and octreotide LAR 30 mg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yao, James C., Phan, Alexandria T., Chang, David Z., Wolff, Robert A., Hess, Kenneth, Gupta, Sanjay, Jacobs, Carmen, Mares, Jeannette E., Landgraf, Andrea N., Rashid, Asif, Meric-Bernstam, Funda
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2008
Matèries:
Gastrointestinal Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2653122/
https://ncbi.nlm.nih.gov/pubmed/18779618
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.16.7858
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars